Antibodies

#Antibodies #Covid-19 #Research

Critically ill Covid-19 patients have normal antibody production

Researchers at Lawson Health Research Institute (Lawson) and Western University have teamed up with local biotech company, Diagnostics Biochem Canada, to better understand Covid-19 and the body’s immune response to the infection. A recently published study followed 28 critically ill patients at London Health Sciences Centre (LHSC); 14 who tested… Read More

#Covid-19 #News

#Antibodies #Cell therapy #Drug design #Drug technology #Protein Fluidics #Software

Updated platform helps streamline workflows

Sphere Fluidics has enhanced the capability and performance of its Cyto-Mine System. This is an automated platform which integrates single cell screening, sorting, dispensing, imaging and clone verification. The simplified design should help streamline workflows, reduce costs, increase throughput, and enable high-value clones to be captured in a single run. Read More

#News

#Antibodies #Awards #Biologics / Biotechnology #Drug development #Oncology #Therapeutics

Matwin spotlights innovation in the fight against cancer

Matwin has picked four companies that will now receive investment from the French oncology accelerator. This was during the MEET2WIN European Oncology Partnering Convention. Step Pharma was awarded ‘First-in-class therapeutic innovation’. The startup’s lead program (STP938) is based on a novel class of oral nucleotide synthesis inhibitors that target CTPS1… Read More

#News

#Antibodies #Cancer research #Drug development #Research

Flow Eighteen38 reagent antibodies licensed for cancer research

Flow Eighteen38, FairJourney Biologics (FJB) and the Hubrecht Institute are working together to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies for research tools for the group Hans Clevers. The Clevers group is studying molecular mechanisms of tissue development and cancer of various organs using organoids… Read More

#News

#Antibodies #Cell therapy #DNA #Drug delivery #Drug development #Drug discovery #Sequencing

Accelerating antibody discovery by making sequence space accessible

The biggest constraint in discovering new antibodies for immunotherapy is constructing the underlying DNA sequence, says Dr. Aaron Sato, CSO of Twist Bioscience. Inside the human body, the immune system generates antibodies that can target just about any foreign molecule. It does so through DNA recombination and somatic hypermutation –… Read More

#Editor's Choice #Exclusive Content #News

#Antibodies #Assays #Pharmaceuticals #Small molecules

Synthesising new solutions for small molecule antibodies

Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors. Small molecules are ubiquitous in our environment, from toxins and heavy metals… Read More

#Editor's Choice #Exclusive Content #News

#Antibodies #Covid-19 #Drug development #Drug discovery #Therapies #Vaccines

Covid-19 response speed sets a new standard in drug discovery

    This paid-for advertorial by Berkeley Lights appeared in DDW Volume 22, Issue 2 – Spring 2021 The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Several therapeutic antibodies and… Read More

#Covid-19 #Exclusive Content

#Antibodies #Clinical trial #Covid-19 #Immunology / Virology & Vaccines

Trial begins of antibody to treat Covid-19 respiratory disease

A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalised with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes Covid-19, has begun. The Phase II trial, called the Covid-19 anti-CD14 Treatment Trial (CaTT), is… Read More

#Covid-19 #News

#Antibodies #Immune system #Vaccine candidate #Vaccines

How a soccer ball and a computer inform new vaccines

RSV is a complicated virus, and traditional vaccine methods have not worked. But UW’s Institute for Protein Design may have solved the problem using computational design. With the help of an innovative computer program, Icosavax has constructed virus-like particles (VLPs) using a two-part assembly (like a soccer ball). Adam Simpson,… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Start-up Zone

T cells
#Antibodies #Covid-19 #Immunology / Virology & Vaccines #Online focus #Vaccines

T Cells recognise recent SARS-CoV-2 variants

When variants of SARS-CoV-2 emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More

#Covid-19 #News

#Antibodies #Covid-19 #Online focus

Putting function first to find antibodies against difficult target

Three case studies from Berkeley Lights The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Berkeley Lights has established multiple partnerships worldwide to provide access to its platform to rapidly accelerate the… Read More

#Covid-19 #News

#Antibodies #Biologics #Covid-19 #Drug development #Drug discovery #Online focus

IONTAS has identified novel SARS-CoV-2 neutralising antibodies

IONTAS and FairJourney Biologics have identified neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalised COVID-19 patients, identified potent neutralising antibodies with distinct mechanisms of action. Based on this approach, the company has… Read More

#News

#Antibodies #Drug development #Drug discovery #Huntington's disease

Collaboration to develop landmark novel antibody therapy for Huntington’s

Alchemab, a biotech company harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support its collaboration with Medicines Discovery Catapult and the development of a novel disease-modifying antibody therapy for Huntington’s disease. Using its novel approach, Alchemab has… Read More

#News

#Antibodies #Biologics #Biologics / Biotechnology #Cell therapy

IONTAs and FairJourney antibody agreement with Quell Therapeutics

IONTAS and FairJourney Biologics (FJB) have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. A diverse panel of novel target binders from IONTAS and FairJourney Biologics (FJB) will be used to identify antibodies to advance Quell’s engineered Treg cell therapy pipeline. Quell… Read More

#News #Trending News

#Antibodies #Nanobodies

ChromoTek and Absolute Antibody collaborate on recombinant antibodies

ChromoTek, part of Proteintech specialising in nanobody-based reagents, and Absolute Antibody, provider of recombinant antibody technology, have announced a partnership to offer recombinant engineered antibodies to scientists worldwide. The chimeric antibodies were originally derived from alpaca nanobodies and engineered onto mouse and rabbit Fc domains to open up new research… Read More

#News